Modalis Therapeutics Corporation (4883.T)
JPY 81.0
(0.0%)
JPY 81.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.37 Billion JPY | -14.9% |
| 2022 | -2.06 Billion JPY | -66.46% |
| 2021 | -1.23 Billion JPY | -211.14% |
| 2020 | -398.35 Million JPY | -353.73% |
| 2019 | 157 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -490.08 Million JPY | 35.62% |
| 2024 Q2 | -348.86 Million JPY | 28.81% |
| 2023 Q1 | -514.44 Million JPY | 17.68% |
| 2023 Q4 | -761.23 Million JPY | -34.82% |
| 2023 Q3 | -564.64 Million JPY | -6.47% |
| 2023 FY | -2.37 Billion JPY | -14.9% |
| 2023 Q2 | -530.34 Million JPY | -3.09% |
| 2022 Q3 | -569.76 Million JPY | 0.0% |
| 2022 FY | -2.06 Billion JPY | -66.46% |
| 2022 Q4 | -624.96 Million JPY | -9.69% |
| 2021 FY | -1.23 Billion JPY | -211.14% |
| 2020 FY | -398.35 Million JPY | -353.73% |
| 2019 FY | 157 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 146.352% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 101.107% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 99.331% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 101.382% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | -1112.208% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 107.551% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 124.913% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 104.438% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | 431.006% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 118.0% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 140.841% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | 220.672% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | -379.757% |
| Tsumura & Co. | 20.01 Billion JPY | 111.839% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 158.999% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 147.061% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 113.429% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | 161.431% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 124.391% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 139.415% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 23.027% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 160.863% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | -191.991% |
| MedRx Co., Ltd | -933 Million JPY | -154.019% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 146.002% |
| Solasia Pharma K.K. | -1.13 Billion JPY | -108.077% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 136.462% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 112.549% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | -239.816% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 112.26% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 154.081% |